| 20-May-13 08:00AM | Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference PR Newswire -6.06% |
| 17-May-13 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 09-May-13 09:12AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-Apr-13 08:00AM | Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013 Business Wire |
| 29-Mar-13 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 07:55AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of EDGAR Online |
| 22-Mar-13 09:15AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 11-Mar-13 08:00AM | Rexahn Pharmaceuticals to Present at the 25th Annual ROTH Conference Business Wire |
| 19-Feb-13 08:03AM | InPlay: Rexahn Pharmaceuticals provides key goals for 2013; expects to Initiate a Phase I clinical study with RX-5902 Briefing.com -5.41% |
| 08:02AM | Rexahn says to continue RX-3117 development with Teva at theflyonthewall.com |
| 08:00AM | Rexahn Pharmaceuticals Provides Key Goals for 2013 Business Wire |
| 12-Feb-13 08:20AM | U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Marketwired -7.50% |
| 08:20AM | U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Marketwire |
| 11-Feb-13 11:39AM | Cancer Stocks To Watch at Seeking Alpha +17.65% |
| 30-Jan-13 08:12AM | Rexahn initiated with a Buy at Maxim at theflyonthewall.com |
| 22-Jan-13 05:25PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online |
| 04:25PM | 4 Healthcare Stock Stories for Investor Well-Being at Wall St. Cheat Sheet |
| 08:00AM | Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer Business Wire |
| 08-Jan-13 08:20AM | Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012 Marketwire |
| 04-Jan-13 10:24AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 02-Jan-13 10:02AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 28-Dec-12 01:09PM | Marvell Initiated at Hold and 2 Initiated Stocks on the Move at Wall St. Cheat Sheet +10.34% |
| 10:01AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 27-Dec-12 11:30PM | Coverage initiated on Rexahn Pharmaceuticals by Burrill Institutional Research Briefing.com |
| 17-Dec-12 08:00AM | Rexahn Pharmaceuticals Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds Business Wire |
| 13-Dec-12 08:05AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events EDGAR Online -6.45% |
| 10-Dec-12 04:25PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04-Dec-12 04:35PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:00PM | Rexahn Pharmaceuticals Closes Public Offering for $6,600,000 in Gross Proceeds Business Wire |
| 30-Nov-12 09:29AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial EDGAR Online |
| 29-Nov-12 09:05AM | InPlay: Rexahn Pharmaceuticals prices underwritten public offering of 19,130,435 shares of its common stock and warrants exercisable for up to 10,521,739 additional shares at $0.33 per fixed combination of shares and warrants for gross proc Briefing.com -31.91% |
| 09:00AM | Rexahn Pharmaceuticals Prices Public Offering of Stock Business Wire |
| 28-Nov-12 05:44PM | Sarepta Gains From Vertex Info, Teva Buys Rexahn Stock: Healthcare Business Wrap at Wall St. Cheat Sheet +9.30% |
| 04:32PM | InPlay: Rexahn Pharmaceuticals announces proposed public offering of common stock and warrants Briefing.com |
| 04:32PM | Rexahn Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrant Business Wire |
| 08:00AM | Teva Pharmaceutical to Increase Ownership in Rexahn Business Wire |
| 27-Nov-12 08:33AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial EDGAR Online |
| 21-Nov-12 08:02AM | Rexahn Pharmaceuticals issued U.S. patent for quinoxalinyl-piperazine compounds theflyonthewall.com |
| 08:00AM | InPlay: Rexahn Pharmaceuticals issued US patent for Quinoxalinyl-piperazine compounds Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Issued US Patent for Quinoxalinyl-piperazine Compounds Business Wire |
| 16-Nov-12 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 08-Nov-12 04:36PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 26-Sep-12 08:00AM | InPlay: Rexahn Pharmaceuticals granted European patent for novel anti-cancer isoquinolinamine compounds Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds Business Wire |
| 06-Sep-12 08:00AM | Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference Business Wire |
| 04-Sep-12 08:06AM | InPlay: Rexahn Pharmaceuticals provides update on 2012 strategic goals; in continuing dialogue with a range of potential partners and continues new CEO search Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Provides Update on 2012 Strategic Goals Business Wire |
| 31-Aug-12 07:41AM | Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta at TheStreet |
| 30-Aug-12 08:00AM | Rexahn Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference Business Wire -9.43% |
| 29-Aug-12 10:31AM | Rexahn Pharmaceuticals, Seven Arts Pictures Gapping Up Wednesday at Fox Business |
| 28-Aug-12 03:41PM | Healthcare Review: Discovery Laboratories & Rexahn Pharmaceuticals Jump, Catalyst Pharmaceutical Slump Thomson Reuters ONE +17.02% |
| 08:50AM | InPlay: Rexahn Pharmaceuticals announced earlier positive top-line Phase IIa data for Archexin in patients with metastatic pancreatic cancer Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer Business Wire |
| 15-Aug-12 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 08-Aug-12 03:31PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 06-Aug-12 08:02AM | Rexahn Pharmaceuticals completes exploratory Phase I RX-3117 study at theflyonthewall.com +6.12% |
| 08:00AM | Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117 Business Wire |
| 12-Jul-12 11:31AM | NetSol Technologies, Rexahn Pharmaceuticals Gapping Up Thursday at Fox Business -5.17% |
| 10:57AM | NetSol Technologies, Rexahn Pharmaceuticals Gapping Up Thursday at Fox Business |
| 06-Jul-12 01:18PM | Boston Beer Co. INTRODUCES New Summer Lager and 4 End-of-Week Hot Stocks at Wall St. Cheat Sheet +20.37% |
| 02-Jul-12 08:02AM | Rexahn Pharmaceuticals subits IND to FDA for RX-5902 at theflyonthewall.com +9.38% |
| 08:01AM | InPlay: Rexahn Pharmaceuticals submits an investigational new drug application to the FDA for first-in-class p68 Helicase Inhibitor, RX-5902 Briefing.com |
| 08:00AM | Rexahn Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902 Business Wire |
| 21-Jun-12 04:10PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 30-May-12 08:11AM | InPlay: Rexahn Pharmaceuticals announces publication of new preclinical research data for novel anti-cancer compound RX-3117 Briefing.com |
| 08:09AM | Rexahn Pharmaceuticals' anti-cancer compound shows positive results in research theflyonthewall.com |
| 08:00AM | Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117 Business Wire |
| 18-May-12 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials -6.98% |
| 17-May-12 12:00PM | Rexahn Pharmaceuticals: Update On Cancer Drugs at Seeking Alpha |
| 09-May-12 04:07PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08-May-12 08:01AM | InPlay: Rexahn Pharmaceuticals submits Archexin Phase II protocol for ovarian cancer to FDA Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA Business Wire |
| 30-Apr-12 08:04AM | Rexahn Pharmaceuticals issued Japanese patent for new anti-cancer compunds at theflyonthewall.com |
| 08:00AM | Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds Business Wire |
| 30-Mar-12 03:34PM | Rexahn Pharmaceuticals Focus On Cancer May Pay Off at Seeking Alpha |
| 27-Mar-12 08:00AM | Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting Business Wire |
| 22-Mar-12 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 16-Mar-12 06:03AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 13-Mar-12 08:00AM | Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 Business Wire |
| 25-Jan-12 08:02AM | InPlay: Rexahn Pharmaceuticals publishes new preclinical data for Quinoxalinyl-Piperazine Compounds - various new quinoxalinyl-piperazine derivatives were shown to have excellent anti-proliferative activity against different human cancer ce Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds Business Wire |
| 18-Jan-12 08:01AM | InPlay: Rexahn Pharmaceuticals secures approval in Europe to conduct a First-in-Human trial of RX-3117 in solid tumors Briefing.com +16.28% |
| 08:00AM | Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors Business Wire |
| 17-Jan-12 05:19PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 08:14AM | InPlay: Rexahn Pharmaceuticals provided guidance on its key pipeline, scientific and business goals for 2012; expects to file an Investigational New Drug application for a first-in-human clinical trial for RX-5902 Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Provides Key Goals for 2012 Business Wire |
| 17-Nov-11 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials +5.88% |
| 09-Nov-11 05:16PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 09:55AM | Inhibitex: This Is One You Might Want To Grow With at Seeking Alpha |
| 08:16AM | Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests Marketwire |
| 05-Nov-11 04:51PM | Inhibitex Investors: Why Shares Popped 115% at Motley Fool |
| 04-Nov-11 07:28PM | You Should Have Seen These Biotech Failures Coming at Motley Fool -33.33% |
| 05:13PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 08:01AM | InPlay: Rexahn Pharmaceuticals announces Phase II results for Serdaxin as treatment for major depressive disorder - all groups showed an approximate -14 point improvement Briefing.com |
| 08:00AM | Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder Business Wire |
| 12-Oct-11 08:00AM | Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds Business Wire |
| 03-Oct-11 08:00AM | Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin® Business Wire |
| 28-Sep-11 12:05PM | Rexahn Pharmaceuticals advances pancreatic cancer drug at bizjournals.com |
| 08:03AM | Rexahn Pharmaceuticals completes enrollment for Archexin Phase II trial theflyonthewall.com |
| 08:01AM | InPlay: Rexahn Pharmaceuticals completes patient enrollment for Archexin Phase II clinical trial in metastatic pancreatic cancer Briefing.com |
